Foundayo™ (Orforglipron): The Once-Daily Oral GLP-1 Weight Loss Pill
Foundayo™ (orforglipron) is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and Company for chronic weight management. Unlike injectable GLP-1 medications, Foundayo is taken as a tablet, offering an alternative administration option for eligible patients. Foundayo was approved by the U.S. Food and Drug Administration (FDA) in April 2026 for chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related health condition. It is not currently available in the UK.
What Makes Foundayo Different?
Oral GLP-1 Treatment
Foundayo is the first approved oral, non-peptide GLP-1 receptor agonist for weight management. As a tablet, it offers an alternative to injectable GLP-1 treatments.
Flexible Administration
Unlike some oral GLP-1 medicines that require strict timing around food and water intake, Foundayo can be taken at any time of day, with or without food.
Small-Molecule Design
Foundayo is a small-molecule, non-peptide medicine designed to activate GLP-1 receptors. This structure allows it to be taken orally without the administration requirements associated with peptide-based therapies.
How Does Foundayo Work?
Foundayo contains orforglipron, which activates GLP-1 receptors involved in appetite regulation and food intake.
GLP-1 receptor agonists may help to:
- Reduce appetite
- Increase feelings of fullness after eating
- Slow stomach emptying
- Support blood sugar regulation
These effects can contribute to weight management when combined with dietary and lifestyle changes.
Current Availability
Foundayo received FDA approval in the United States in April 2026 for chronic weight management. At the time of writing, it has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and is not available for prescribing in the UK.
Key Takeaways
- Foundayo (orforglipron) is a once-daily oral GLP-1 receptor agonist.
- It is the first approved non-peptide GLP-1 tablet for chronic weight management.
- The tablet can be taken with or without food and does not require injection.
- Foundayo is approved in the United States but is not currently available in the UK.
- Regulatory reviews and availability may change as additional approvals are sought globally.
Important Information
Foundayo is a prescription-only medicine approved in the United States. This article is for educational purposes only and does not constitute medical advice. Availability, licensing status and prescribing guidance may differ between countries.
